A glycine at position 105 leads to clavulanic acid and avibactam resistance in class A β-lactamases
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Marko Radojković und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Macromolecular Biochemistry, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands. Hauptthemen laut MEDLINE: beta-Lactamases, Clavulanic Acid, beta-Lactamase Inhibitors, Azabicyclo Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderzoek, European Synchrotron Radiation Facility, Universiteit Leiden.
Abstract (Originalsprache)
β-Lactamase enzymes exhibit extraordinary adaptive potential, thus rendering many β-lactam drugs ineffective. The residue at Ambler position 105, also known as the gatekeeper residue, plays an important role in substrate recognition, but its implication in inhibition mechanisms remains understudied and obscure. To inspect the relationship between inhibitor-resistant phenotypes and residues at this position, we performed site-saturation mutagenesis and extensive fitness profiling of five distinct class A β-lactamases using deep sequencing. We found that inhibitor resistance is readily detectable, with variants harboring Gly or Arg being the least susceptible to inhibitors. Mutation of Ile105 to Arg in the β-lactamase BlaC simultaneously enhances activity for carbenicillin and the ability to evade clavulanic acid inhibition. The Y105G substitution in two clinically important enzymes, CTX-M-14 and TEM-1, confers greatly reduced in vitro sensitivity to avibactam, which we attribute to elevated conformational flexibility of the inhibitor within the active site. The findings presented in this study underpin the gatekeeper residue as a possible mutational hotspot and might aid the design of novel β-lactamase inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Macromolecular Biochemistry, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
- Department of Macromolecular Biochemistry, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Macromolecular Biochemistry, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands; School of Chemistry, University of Bristol, Bristol, United Kingdom.
- Department of Macromolecular Biochemistry, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands. Electronic address: m.ubbink@chem.leidenuniv.nl.
Förderung
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- European Synchrotron Radiation Facility
- Universiteit Leiden
Zitieren
APA
Radojković, M., Chikunova, A., Koene, S. F., Timmer, M., Natarajan, S. V., Boyle, A. L., & Ubbink, M. (2025). A glycine at position 105 leads to clavulanic acid and avibactam resistance in class A β-lactamases. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110347
Vancouver
Radojković M, Chikunova A, Koene SF, Timmer M, Natarajan SV, Boyle AL, et al. A glycine at position 105 leads to clavulanic acid and avibactam resistance in class A β-lactamases. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110347
BibTeX
@article{Radojkovi2025,
author = {Radojković, Marko and Chikunova, Aleksandra and Koene, Saar F and Timmer, Monika and Natarajan, Sivanandam V and Boyle, Aimee L and Ubbink, Marcellus},
title = {A glycine at position 105 leads to clavulanic acid and avibactam resistance in class A β-lactamases},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110347}
}
EUVIMED